The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.
Agents with novel mechanisms, including bispecific antibodies, immunomodulatory drugs, and antibody-drug conjugates, are displaying promising results in patients with relapsed or refractory multiple myeloma.
Baseline ocular conditions not related to the cornea have little effect on treatment-emergent adverse effects that may arise with belantamab mafodotin in patients with relapsed/refractory multiple myeloma.
Extended treatment with carfilzomib plus lenalidomide and dexamethasone after autologous stem cell transplant improved progression-free survival over standard lenalidomide maintenance in patients with multiple myeloma.
The combination of Isatuximab plus carfilzomib and dexamethasone continued to demonstrate a progression-free survival benefit vs carfilzomib and dexamethasone alone in relapsed multiple myeloma.
The triplet regimen of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplantation and lenalidomide maintenance therapy significantly improved progression-free survival compared with RVd alone in patients with newly diagnosed multiple myeloma, with notable benefit observed in those with high-risk cytogenetics.
Treatment with daratumumab plus lenalidomide and dexamethasone for at least 18 months led to deep clinical responses in patients with treatment-naïve multiple myeloma who were transplant ineligible.
Induction and consolidation therapy with a combination comprised of daratumumab, carfilzomib, lenalidomide, and dexamethasone allowed 70% of patients with high-risk, newly diagnosed multiple myeloma to complete a second autologous stem cell transplant.
Isatuximab plus pomalidomide and dexamethasone elicited favorable progression-free survival and proved tolerable in pretreated patients with relapsed/refractory multiple myeloma.
The addition of ixazomib to daratumumab, pomalidomide, and dexamethasone has elicited deep and durable response rates with a manageable safety profile as salvage therapy in patients with relapsed/refractory multiple myeloma.
Closing out their discussion on novel agents in multiple myeloma, expert panelists consider remaining unmet needs and future evolutions in the treatment paradigm.
Key opinion leaders consider the potential for CAR T-cell therapy in earlier lines of therapy for patients with multiple myeloma.
The European Commission has granted conditional marketing authorization to teclistamab for use as a single agent in adult patients with relapsed and refractory multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.